



Nanoparticle Biochem, Inc

Contact: Anandhi Upendran
Location: Columbia, MO, USA
Email: upendrana@missouri.edu
Tel: 573.639.2619
Website: www.nanoparticlebiochem.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Overview

Industry Sector: Nanopharmaceutical

Company Overview: Nanoparticle Biochem Inc (NBI) was established through ground breaking original discoveries on the design and development of various types of metallic and radioactive nanoconjugates.

Target Market(s): Major radiation oncology hospitals worldwide.

Key Value Drivers

Technology: Nanoparticle Biochem, Inc (NBI) has developed a radioactive gold nanoconstruct-based therapeutic agent, S-NBI-29, for treating inoperable prostate cancer.

Competitive Advantage: NBI is uniquely positioned in the nanopharmaceutical industry with definite competitive advantages. S-NBI-29 is the first injectable liquid nano-brachy agent and is expected to serve as highly efficient and non-toxic alternative for implantable radioactive devices for treating prostate tumors.

Plan & Strategy: seeking a strategic partner

Management

Leadership:

Henry W White, President and CEO
Raghuraman Kannan, Chief Strategy Officer
Anandhi Upendran, Director of Research
Kattesh V Katti, Vice President
Suzan Anne Moser-Director of Clinical Affairs

Scientific Advisory Board:

Wynn Volkert, Ph.D.: Curators Professor of Radiology Biochemistry at the University of Missouri
Carl Freter, MD Ph.D.: Professor of Hematology and Oncology, University of Missouri
Cathy S Cutler, Ph.D: Research Professor, Missouri University Research Reactor, University of Missouri.

Product

Product Pipeline

Table with 4 columns: Discovery, Pre-clinical Mice, Pre-clinical Dogs, Pre-IND. Rows include Radiopharmaceuticals (S-NBI-29, S-NBI-70) and Nanopharmaceuticals (GNR-29, NBI-90).